HC Wainwright & Co. Maintains Buy on Karyopharm Therapeutics, Lowers Price Target to $26
HC Wainwright & Co. analyst Edward White maintains Karyopharm Therapeutics (NASDAQ:KPTI) with a Buy and lowers the price target from $49 to $26.
SVB Leerink Downgrades Karyopharm Therapeutics to Market Perform, Announces $6 Price Target
SVB Leerink analyst Jonathan Chang downgrades Karyopharm Therapeutics (NASDAQ:KPTI) from Outperform to Market Perform and announces $6 price target.
RBC Capital Downgrades Karyopharm Therapeutics to Sector Perform, Lowers Price Target to $8
RBC Capital analyst Brian Abrahams downgrades Karyopharm Therapeutics (NASDAQ:KPTI) from Outperform to Sector Perform and lowers the price target from $17 to $8.
JP Morgan Downgrades Karyopharm Therapeutics to Underweight
JP Morgan analyst Eric Joseph downgrades Karyopharm Therapeutics (NASDAQ:KPTI) from Overweight to Underweight.
Stocks That Hit 52-Week Lows On Thursday
During Thursday's morning session, 77 companies made new 52-week lows.
The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 4)
Karyopharm Therapeutics Q2 EPS $(0.71) Beats $(0.74) Estimate, Net PRoduct Revenue $20.2M
Karyopharm Therapeutics (NASDAQ:KPTI) reported quarterly losses of $(0.71) per share which beat the analyst consensus estimate of $(0.74) by 4.05 percent. This is a 12.7 percent decrease over losses of $(0.63) per share